Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© Painting by Marta Murphy - Bjorkman Lab

Researchers from the Townsend Group have collaborated with the Howarth Lab (University of Cambridge) and the Bjorkman Group (Caltech) to develop an improved version of a novel all-in-one vaccine against coronavirus threats. Results from this study have been published in the journal Nature Nanotechnology.

Previous work by the Townsend and Bjorkman groups contributed to the development of a nanoparticle vaccine (Mosaic-8b RBD-mi3), which was able to target multiple different types of SARS-like betacoronaviruses (sarbecoviruses). This vaccine should enter Phase 1 clinical trials early next year. However, the complex nature of this vaccine makes it challenging to manufacture, which could limit large-scale production of the vaccine in the future. In this new study, the authors present an updated version of the vaccine that should be simpler to make.

The Mosaic-8 vaccine developed previously featured Receptor Binding Domains (RBDs) from eight different coronaviruses. RBDs are parts of the viral spike protein that are targeted by antibodies, host proteins that are raised by the immune system in response to pathogens. These eight RBDs were ‘glued’ onto a nanocage structure, allowing one vaccine to present the eight different domains and generate an immune response. The Mosaic-8 vaccine was shown to provide protection against a diverse range of sarbecoviruses, not just the eight with RBDs included in the vaccine.

The new Quartet Nanocage vaccines were able to produce a level of immune responses and protection against coronaviruses that were similar, if not better, than the Mosaic-8 vaccine. Another advantage of the Quartet Nanocages is the ability to display more RBDs. The Quartet Nanocage design allows four RBDs to be displayed from one site on the nanocage, rather than needing four individual sites as is the case with the Mosaic-8 design.

Rory Hills, first author of the paper, said:

We have shown that a relatively simple vaccine can produce a protective response for several coronaviruses. This is an important step towards our goal of creating vaccines for pandemic threats before they are able to infect humans.

Read the full paper here: https://www.nature.com/articles/s41565-024-01655-9

Hear from first author Rory Hills in this video produced by the Department of Pharmacology, University of Cambridge: https://youtu.be/UCQl4dBttOg

Recent stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.